DDInter1835 DDInter899
An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA topoisomerases, type I.
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval; however, in April 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US. Ibrutinib was approved by the EMA in October 2014 and by Health Canada in November 2014. It is currently approved for the treatment of various conditions, such as chronic lymphocytic leukemia (CLL), Waldenström's Macroglobulinemia, and chronic graft versus host disease (cGVHD) in August 2017. Notably, ibrutinib became the first FDA-approved cGVHD treatment for children in August 2017.
Topotecan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Irinotecan
Topotecan {u} (Compound) treats {v} (Disease) peripheral nervous system neoplasm
Topotecan {u} (Compound) binds {v} (Gene) TOP1
Topotecan {u} (Compound) upregulates {v} (Gene) ALDH5A1
Topotecan {u} (Compound) is included by {v} (Pharmacologic Class) Topoisomerase Inhibitors
Topotecan {u} (Compound) downregulates {v} (Gene) CCNF
Topotecan {u} (Compound) causes {v} (Side Effect) Mucosal inflammation
Topotecan {u} may cause a minor interaction that can limit clinical effects when taken with {v} Gemifloxacin
Topotecan {u} may cause a minor interaction that can limit clinical effects when taken with {v} Enoxacin
Topotecan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cabazitaxel
Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Irinotecan
Topotecan (Compound) treats peripheral nervous system neoplasm (Disease)
Topotecan (Compound) binds TOP1 (Gene)
Topotecan (Compound) upregulates ALDH5A1 (Gene)
Topotecan (Compound) is included by Topoisomerase Inhibitors (Pharmacologic Class)
Topotecan (Compound) downregulates CCNF (Gene)
Topotecan (Compound) causes Mucosal inflammation (Side Effect)
Topotecan may cause a minor interaction that can limit clinical effects when taken with Gemifloxacin
Topotecan may cause a minor interaction that can limit clinical effects when taken with Enoxacin
Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel